Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 6/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 6/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5962824 | 0.92 | PKM (0.53) | TRPV1ROCK2PKMHCRTR1HCRTR2 | |
| SCHEMBL5962832 | 0.83 | ROCK2 (0.46) | TRPV1ROCK2HCRTR1HCRTR2TLR8 | |
| SCHEMBL5962794 | 0.82 | SPHK2 (0.51) | TRPV1ROCK2PKMHCRTR1HCRTR2 | |
| SCHEMBL14071789 | 0.82 | KDM4E (0.50) | TRPV1ROCK2HCRTR1HCRTR2TLR8 | |
| SCHEMBL4415353 | 0.82 | KDM4E (0.50) | TRPV1ROCK2HCRTR1HCRTR2TLR8 | |
| SCHEMBL5962928 | 0.81 | LMNA (0.49) | TRPV1ROCK2HCRTR1HCRTR2DRD2 | |
| SCHEMBL5962802 | 0.77 | ROCK2 (0.45) | TRPV1ROCK2HCRTR1HCRTR2DRD2 | |
| SCHEMBL29687727 | 0.77 | KDM4E (0.45) | TRPV1ROCK2HCRTR1HCRTR2TLR8 | |
| SCHEMBL20527195 | 0.76 | TRPV1 (0.46) | TRPV1ROCK2HCRTR1HCRTR2RAB9A | |
| SCHEMBL20527192 | 0.76 | TRPV1 (0.46) | TRPV1ROCK2HCRTR1HCRTR2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7067511-B2 | Pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2006-06-27 | — | — | US | disclosed |
| US-7049311-B1 | Pyrrolbenzodiazepines | SPIROGEN LIMITED (GB) | 2006-05-23 | — | — | US | disclosed |
| EP-1109812-B1 | PYRROLOBENZODIAZEPINES | SPIROGEN LTD (GB) | 2005-05-04 | — | — | EP | disclosed |
| EP-1413582-A1 | Dimeric pyrrolobenzodiazepines | Spirogen Limited (GB) | 2004-04-28 | — | — | EP | disclosed |
| US-20030120069-A1 | Pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2003-06-26 | — | — | US | disclosed |
| EP-1193270-A2 | Pyrrolobenzodiazepines | Spirogen Limited (GB) | 2002-04-03 | — | — | EP | disclosed |
| EP-1109812-A2 | PYRROLOBENZODIAZEPINES | Spirogen Limited (GB) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000012508-A2 | PYRROLBENZODIAZEPINES | SPIROGEN LIMITED (GB) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030120069-A1 | Pyrrolobenzodiazepines | CNR1, CBX2, CNR2 | TRPV1 3319/4885ROCK2 2527/4885PKM 3354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.